According to our results, variants in ADAMTS1, BZRAP1-AS1, and CELF1 affect the mechanisms involved both in brain amyloidosis and neurodegeneration, CD2AP in brain tauopathy and neurodegeneration, and SLC24A4/RIN3 in brain amyloidosis and tauopathy (Fig. 4), implying these genes might contribute to AD risk via either common or distinct mechanisms. This evidence concerns the gene CD2AP and tauopathy.